Cutaneous porphyrias part II: treatment strategies.

Item

http://www.wikidata.org/entity/Q38153429

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Cutaneous porphyrias part II: treatment strategies.

@en

type

Item

label

Cutaneous porphyrias part II: treatment strategies.

@en

prefLabel

Cutaneous porphyrias part II: treatment strategies.

@en

P1476

Cutaneous porphyrias part II: treatment strategies.

@en

P2093

Ali Alikhan

http://www.w3.org/2001/XMLSchema#string

Dawn Marie R Davis

http://www.w3.org/2001/XMLSchema#string

Jennifer L Hand

http://www.w3.org/2001/XMLSchema#string

Mary E Horner

http://www.w3.org/2001/XMLSchema#string

Suzanne Tintle

http://www.w3.org/2001/XMLSchema#string

P2860

Characterization of mutations in the CPO gene in British patients demonstrates absence of genotype-phenotype correlation and identifies relationship between hereditary coproporphyria and harderoporphyria.

Variegate porphyria in Western Europe: identification of PPOX gene mutations in 104 families, extent of allelic heterogeneity, and absence of correlation between phenotype and type of mutation

Effective gene therapy of mice with congenital erythropoietic porphyria is facilitated by a survival advantage of corrected erythroid cells

Porphyria cutanea tarda as a complication of therapy for chronic hepatitis C

Screening for mutations in the uroporphyrinogen decarboxylase gene using denaturing gradient gel electrophoresis. Identification and characterization of six novel mutations associated with familial PCT

Recognizing and treating cutaneous signs of liver disease

Change in moles linked to use of unlicensed "sun tan jab"

4-Norleucine, 7-D-phenylalanine-alpha-melanocyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity

Effect of zinc or S-adenosyl-l-methionine on long term administration of low doses of lead to rats

Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions.

P304

3-24

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/IJD.12016

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-10-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258054038

http://www.w3.org/2001/XMLSchema#string

P698

24134210

http://www.w3.org/2001/XMLSchema#string